The first quarter of 2017 witnessed a surge in Securities Class Action filings. In addition, merger objection litigation continued at a relatively high rate. A significant driver of this has been the prominence of litigation involving companies in the pharmaceutical and biotech industries. The April 27th Webinar discussed differences between the two industries and the drivers of litigation.
Speaking Engagements April 27, 2017